Effectiveness of nicotine replacement therapy on smoking cessation among pulmonary tuberculosis patients of Mangaluru, India: A randomized controlled trial (Preprint)

This study examined if 2-week free nicotine replacement therapy (NRT) would be more effective than 1-week free NRT to help smokers quit smoking at 6 and 12 months. In a single-blinded randomized controlled trial design, 562 Chinese smokers who attended a smoking cessation clinic in Hong Kong, China, were randomly allocated into two groups (A1 and A2): A1 (n=284) received behavioural counselling with free NRT for 1 week; A2 (n=278) received similar counselling with free NRT for 2 weeks. All subjects received printed self-help materials to support their quitting efforts. A structured questionnaire was used for data collection, including pattern of NRT use and self-reported 7-day point prevalence quit rate at 6 months and 12 months. Among the participants, the mean number of cigarettes smoked per day was 18.8 (SD=10.9). By intention-to-treat analysis, 7-day point prevalence quit rates were not significantly different between A1 and A2 groups at 6-month (27.5% versus 27.3%;P=0.97) and 12-month (21.1% versus 21.2%;P=0.98) followup. The findings suggest that two-week free NRT was not more effective than 1-week free NRT to increase smoking cessation rate among Chinese smokers.

Download Full-text

Effectiveness of nicotine replacement therapy on smoking cessation among pulmonary tuberculosis patients of Mangaluru, India: A randomized controlled trial (Preprint)

10.2196/preprints.17938 ◽

2020 ◽

Author(s):

Keyword(s):

Smoking Cessation ◽

Pulmonary Tuberculosis ◽

Replacement Therapy ◽

Nicotine Replacement Therapy ◽

Smoking Status ◽

Controlled Trial ◽

Control Group ◽

Nicotine Replacement ◽

Tuberculosis Patients ◽

Brief Advice

UNSTRUCTURED Tuberculosis and tobacco smoking are two largely preventable public health concerns that independently pose a considerable threat to global health. The current estimates put the annual global mortality from the two epidemics at over six million. It is remarkable to note that TB and tobacco use are co-prevalent in many developing nations and these are said to be overburdened by the collision of the two epidemics. This study aims to determine the effectiveness of nicotine replacement therapy on smoking cessation among the pulmonary tuberculosis patients undergoing Directly Observed Therapy- Short Course. This is a randomized, placebo-controlled, two-arm, single blinded trial being conducted in Mangaluru, India. The total sample size including both the arms is 300. This study will be conducted between January 2019 and August 2020. Extra-pulmonary TB, smokeless tobacco users, patients with contraindications for NRT such as recent MI, angina pregnancy & lactation will be excluded from the study.Block Randomization will be done to obtain the two groups using a permuted The experimental group will be given nicotine replacement therapy and brief advice and the control group will be given brief advice and sugar-free chewing gum as a placebo for 3 months on a tapering dosage basis. The smoking status of the patients will be confirmed by urine cotinine test at the baseline and endline. Carbon monoxide monitoring and Fagerstom score will be recorded on a monthly basis.The participants will be followed for another 3 months to obtain a binary variable of smoking cessation status as "Quitter" or Non-quitter". The study also determines the TB outcome between tobacco quitters and non-quitters. Ethical clearance is obtained from the Institutional Ethics Committee of Nitte (deemed to be University) and the trial is registered with Clinical Trials Registry of India.

Download Full-text

Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial

Addiction ◽

10.1111/j.1360-0443.2011.03419.x ◽

2011 ◽

Vol 106 (6) ◽

pp. 1176-1185 ◽

Cited By ~ 20

Author(s):

Natalie Walker ◽

Colin Howe ◽

Chris Bullen ◽

Michele Grigg ◽

Marewa Glover ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Smoking Cessation ◽

Replacement Therapy ◽

Nicotine Replacement Therapy ◽

Controlled Trial ◽

Nicotine Replacement ◽

Randomized Controlled

Download Full-text

QuitNic: A Pilot Randomized Controlled Trial Comparing Nicotine Vaping Products With Nicotine Replacement Therapy for Smoking Cessation Following Residential Detoxification

Nicotine & Tobacco Research ◽

10.1093/ntr/ntaa143 ◽

2020 ◽

Author(s):

Billie Bonevski ◽

Victoria Manning ◽

Olivia Wynne ◽

Coral Gartner ◽

Ron Borland ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Smoking Cessation ◽

Replacement Therapy ◽

Nicotine Replacement Therapy ◽

Controlled Trial ◽

Pilot Trial ◽

Withdrawal Symptoms ◽

Nicotine Replacement ◽

Behavioral Counseling ◽

Randomized Controlled

Abstract Introduction The QuitNic pilot trial aimed to test the feasibility of providing a nicotine vaping product (NVP) compared with combination nicotine replacement therapy (NRT) to smokers upon discharge from a smoke-free residential substance use disorder (SUD) treatment service. Methods QuitNic was a pragmatic two-arm randomized controlled trial. At discharge from residential withdrawal, 100 clients received telephone Quitline behavioral support and either 12-week supply of NRT or an NVP. Treatment adherence and acceptability, self-reported abstinence, cigarettes smoked per day (CPD), frequency of cravings, and severity of withdrawal symptoms were assessed at 6 and 12 weeks. Results are reported for complete cases and for abstinence outcomes, penalized imputation results are reported where missing is assumed smoking. Results Retention on was 63% at 6 weeks and 50% at 12 weeks. At 12 weeks, 68% of the NRT group reported using combination NRT while 96% of the NVP group used the device. Acceptability ratings for the products were high in both groups. At 12 weeks, 14% of the NVP group and 18% of the NRT group reported not smoking at all in the last 7 days. Mean CPD among continued smokers decreased significantly between baseline to 12 weeks in both groups; from 19.91 to 4.72 for the NVP group (p < .001) and from 20.88 to 5.52 in the NRT group (p < .001). Cravings and withdrawal symptoms significantly decreased for both groups. Conclusions Clients completing residential withdrawal readily engaged with smoking cessation post-treatment when given the opportunity. Further research is required to identify the most effective treatments postwithdrawal for this population at elevated risk of tobacco-related harm. Trial registration number ACTRN12617000849392 Implications This pilot study showed that smoking cessation support involving options for nicotine replacement and Quitline-delivered cognitive behavioral counseling is attractive to people after they have been discharged from SUD treatment. Both nicotine vaping products and nicotine replacement therapies were highly acceptable and used by participants who reported reductions in cravings for cigarettes and perceptions of withdrawal symptoms and reductions in number of cigarettes smoked. Some participants self-reported abstinence from cigarettes—around one in five reported having quit smoking cigarettes at 12 weeks postdischarge. The results have significant public health implications for providing quit support following discharge from SUD treatment.

Download Full-text